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To the Editor,
With the help of improved health care the life
expectancy of an individual is increased, and so is the
need for prostheses. Recent technology has enabled many
people to obtain prostheses, but this also leads to an
increase in prosthesis-related infection (1). Periprosthetic
joint infection (PJI) requires a multidisciplinary approach,
including the correct diagnosis, good surgical care, and
appropriate antibiotic treatment. Surgical interventions
include debridement and retention, one- or two-stage
exchange, and sometimes even arthrodesis or amputation.
The duration of the antibiotic therapy differs according
to the etiologic agent, surgical intervention type, and
laboratory and clinical response of the patient, so the
antibiotic therapy can last from 4–6 weeks to several
months (2). Several antibiotics, especially those with
gram-positive coverage, are used for first-line treatment.
Teicoplanin is among the frequently used antibiotics
because of its gram-positive coverage and the advantage
of once daily use. Because the target coverage of empirical
therapy is affected by different parameters and many
times gram-negative coverage is also provided, empirical
therapy does not seem to be standard in routine practice
in all centers. In this retrospective study we aimed to
review our experience of treatment, particularly the use of
teicoplanin, of a series of PJI cases.
We performed a cross-sectional observational study.
Patients who were diagnosed with acute PJI and followed
in the Ankara Atatürk Training and Research Hospital
between January 2014 and July 2015 were included. The
hospital is a tertiary-care referral hospital and admits
difficult-to-treat PJI cases. The PJI diagnosis was based
on the criteria stated by the clinical practice guidelines of
the Infectious Diseases Society of America and cases of
acutely warm, swollen, painful, erythematous joints were
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diagnosed as “acute PJI” (2,3). The study was performed
in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki. Ethical committee
approval was not needed because of the study design.
Demographic findings and details of the management of
PJI were obtained from the database of the hospital and the
researchers’ records of the patients. Microsoft Excel was
used for statistical analysis. Results are given in numbers
and percentages.
Twenty-two patients with the diagnosis of acute PJI,
either early acute or delayed acute (4), were included: 13
(59%) women and nine (41%) men, with a median age
of 68 years (39–87 years). Ten (45%) patients had PJI of
the hip, while the remaining patients had PJI of the knee
(n = 12, 55%). All patients (100%) presented with warm,
swollen, and painful joints. None of them had wound
discharge. Median laboratory values were as follows:
white blood cell (WBC) count, 7800/µL (5800–15,660/
µL); C-reactive protein (CRP), 35 mg/L (5–93 mg/L); and
erythrocyte sedimentation rate, 55 mm/h (30–107 mm/h).
Five (24%) patients had diabetes mellitus, one (5%) had
rheumatoid arthritis, and three (14%) had malignancy. All
but one of the patients had previous interventions for the
treatment of PJI: either debridement and retention (n =
2, 0.9%) or one-stage (n = 2, 0.9%) or two-stage exchange
operations (n = 17, 77%). The causative agents of PJI are
shown in Table 1. Fifteen (68%) patients received empirical
antibiotic therapy. Details of antibiotic therapies for the
management of PJI were available for 19 patients (Table
2). In five (23%) patients, rifampicin was added to therapy.
Five patients (23%) needed changes in antibiotic therapy
in follow-up: from ampicillin sulbactam + ciprofloxacin
to teicoplanin + sulbactam cefoperazone (n = 4, 18%) and
from teicoplanin + ciprofloxacin to antifungal therapy
(n = 1, 5%) according to either clinical unresponsiveness
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Table 1. Causative agents of PJI (n = 22).
n (%)
Gram-positive

9 (41)

Staphylococcus aureus

2

Coagulase-negative staphylococci

6

Enterococcus faecalis

1

Gram-negative

6 (27)

Escherichia coli

3

Other gram-negative bacteria

3

Fungi

1 (5)

Non-albicans Candida

1

Unknown

6 (27)

or culture results. Other than one patient who needed
multiple operations and suppressive antibiotic therapy,
the other patients responded to therapy (96%). When
those two who were under antifungal therapy and under
suppressive therapy were excluded, the median duration of
antibiotic treatment for two-stage operations was 6 weeks
(4–8 weeks), while it could be prolonged up to 6 months
for one-stage operations. The patient whose treatment was
changed to antifungal therapy needed multiple debridement
after a two-stage exchange operation. Previously he was
under teicoplanin plus ciprofloxacin therapy because of
a PJI caused by Enterococcus faecalis. That PJI was under
control and the prosthesis was removed, but non-albicans
Candida was cultured from tissue and synovial fluid
samples of the patient in the second stage of the operation.
Two more cultures of synovial fluid showed the same
organism afterwards. Antifungal therapy was started with
amphotericin B (4 weeks), followed by voriconazole (1

months), and later continued with fluconazole for up to 1
year in duration. He recovered without any sequelae.
In our study, the median WBC count was within
normal limits and CRP levels were increased only by 6- to
7-fold, which was unhelpful for definitive diagnosis. Main
findings for PJI diagnosis were based on some clinical
findings like pain, warmth, swelling, and redness of the
affected joint and in addition to these either purulence
of synovial fluid or growth of the etiologic agent from
tissue or synovial fluid culture. Delayed diagnosis can
cause harmful effects to prostheses. Clinical findings
guided our prompt diagnosis. The empirical therapies of
PJI mainly included broad-spectrum antibiotics because
of the possible nosocomial source of infection in patients
who had multiple operation histories. As seen in our
results, almost one-third of the patients had gram-negative
etiology and the agent was unknown in many patients.
Thus, the empirical treatment had gram-negative coverage
as well. Teicoplanin was the most preferred antibiotic for
gram-positive coverage, with a successful outcome. Still,
one patient needed suppressive antibiotic therapy while
another patient experienced fungal PJI after a long-term
broad-spectrum treatment.
There are limitations of this study. It was a retrospective
study and the relation between therapy duration and exact
clinical and laboratory response was not closely monitored.
Although we have records, the details of synovial fluid
analysis and surgical interventions were not available for
all subjects and this retrospective study cannot state the
success of medical therapy alone. The details of surgical
interventions were lacking for some patients. Synovial
fluid analysis was done for all patients but the detailed
results were not available for all patients.
In conclusion, although there are many advantages
of teicoplanin use in PJI (good soft tissue and bone
concentrations, administration once a day in outpatient
parenteral therapy, tolerability, safety) and it is even

Table 2. Empirical antibiotic therapies for PJI (n = 19).
n (%)

1948

Teicoplanin ± one of the following:
Ciprofloxacin/sulbactam cefoperazone/imipenem/piperacillin tazobactam

9 (47)

Ampicillin sulbactam ± ciprofloxacin

4 (21)

Ertapenem

2 (11)

Daptomycin

1 (5)

Fusidic acid

1 (5)

Trimethoprim-sulfamethoxazole

1 (5)

Cefazolin

1 (5)

KOÇAK TUFAN et al. / Turk J Med Sci
suggested for the prophylaxis (4), randomized, controlled,
prospective studies (which are already planned by the
authors of this study, according to results of a current

observational study) are needed for documenting its
advantages in cases of PJI.
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